GL1X · GenesisL1 explorer

MolNFT v1 · #125106 · protein

MARK2 complex with 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-5,5-dimethyl-2-(3- PYRIDYLAMINO)PYRROLO[2,3-D]PYRIMIDIN-6-one

5KZ7 · SERINE/THREONINE-protein kinase MARK2: “MARK2 complex with 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-5,5-dimethyl-2-(3…”. X-ray diffraction, 1 ligand (6Z2), 6 pockets (best druggability 0.68). MolNFT v1 #125106 on GenesisL1: 3D structure…

PDB
5KZ7
Type
protein
Length
592 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
SERINE/THREONINE-protein kinase MARK2
EC
2.7.11.1, 2.7.11.26
UniProt
Q7KZI7
Ligands
6Z2
Pockets
6 · best druggability 0.68

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BSERINE/THREONINE-protein kinase MARK2 (EC 2.7.11.1, 2.7.11.26)protein29640% helix, 15% strandQ7KZI7

Ligands and binding sites

  • 6Z2 · 7-[(1~{S})-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(pyridin-3-ylamino)pyrrolo[2,3-d]pyrimidin-6-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16930.680.76676Z2
25620.640.75536Z2
32170.530.7727empty
4850.510.8320empty
51890.490.7629empty

Interfaces

1 interface between chains.

  • A–B · 898 Ų buried · 14 hydrogen bonds · protein-protein

Compared structures

  • 5KZ7 · Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q7KZI7 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase MARK2 (Q7KZI7) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.